Patient characteristics and ALL phenotypes
| No. . | Age, y/Sex . | ALL subtype (genetics) . | Response to primary treatment . | Treatment of relapsed/ refractory disease or MRD positivity . | Emergence of CD19− clone (flow cytometry)/ hematological relapse . | Initial phenotype (before blinatumomab) . | Phenotype at CD19− relapse (after blinatumomab) . |
|---|---|---|---|---|---|---|---|
| 1 | 60/M | Pre B-ALL | GMALL Elderly 1/2003: Persistence of CD19+ blasts after second consolidation (week 24) | Blinatumomab phase 2 study (NCT01466179) | After second blinatumomab course/ after third blinatumomab course | CD19+/CD34+/CD10+/ CD45(+)/cyTdT+/ cyCD79a+/cyCD22+/ cyIgM+ | CD19−/otherwise identical to initial phenotype |
| 2 | 30/F | c-ALL | GMALL 7/2003: Relapse with CD19+ blasts at second reinduction (week 30) | Blinatumomab phase 2 study (NCT01466179) | After second blinatumomab course/ after third blinatumomab course | CD19+/CD34+/CD10+/ CD45(+)/HLA-DR+/ cyTdT+/cyCD79a+ | CD19−/otherwise identical to initial phenotype |
| 3 | 65/M | Pro B-ALL (t(11;19)) | GMALL Elderly 1/2003: MRD+ after second consolidation (week 24) | Blinatumomab phase 2 study (NCT00560794) | After second blinatumomab course/ after second blinatumomab course | CD19+/CD34+/ CD10−/CD45(+)/ HLA-DR(+)/cyTdT+ | CD19−/otherwise identical to initial phenotype |
| 4 | 74/F | c-ALL (trisomy 9, monosomy 7 and 3, 6q21+, 6q23+) | GMALL Elderly 1/2003: Relapse with CD19+ blasts at first reinduction (week 24) | Blinatumomab phase 2 study (NCT01466179) | 19 mo after completion of blinatumomab/ 19 mo after completion of blinatumomab | CD19+/CD34+/CD10(+)/ CD45(+)/cyTdT+/ CD20+ | CD19−/otherwise identical to initial phenotype |
| No. . | Age, y/Sex . | ALL subtype (genetics) . | Response to primary treatment . | Treatment of relapsed/ refractory disease or MRD positivity . | Emergence of CD19− clone (flow cytometry)/ hematological relapse . | Initial phenotype (before blinatumomab) . | Phenotype at CD19− relapse (after blinatumomab) . |
|---|---|---|---|---|---|---|---|
| 1 | 60/M | Pre B-ALL | GMALL Elderly 1/2003: Persistence of CD19+ blasts after second consolidation (week 24) | Blinatumomab phase 2 study (NCT01466179) | After second blinatumomab course/ after third blinatumomab course | CD19+/CD34+/CD10+/ CD45(+)/cyTdT+/ cyCD79a+/cyCD22+/ cyIgM+ | CD19−/otherwise identical to initial phenotype |
| 2 | 30/F | c-ALL | GMALL 7/2003: Relapse with CD19+ blasts at second reinduction (week 30) | Blinatumomab phase 2 study (NCT01466179) | After second blinatumomab course/ after third blinatumomab course | CD19+/CD34+/CD10+/ CD45(+)/HLA-DR+/ cyTdT+/cyCD79a+ | CD19−/otherwise identical to initial phenotype |
| 3 | 65/M | Pro B-ALL (t(11;19)) | GMALL Elderly 1/2003: MRD+ after second consolidation (week 24) | Blinatumomab phase 2 study (NCT00560794) | After second blinatumomab course/ after second blinatumomab course | CD19+/CD34+/ CD10−/CD45(+)/ HLA-DR(+)/cyTdT+ | CD19−/otherwise identical to initial phenotype |
| 4 | 74/F | c-ALL (trisomy 9, monosomy 7 and 3, 6q21+, 6q23+) | GMALL Elderly 1/2003: Relapse with CD19+ blasts at first reinduction (week 24) | Blinatumomab phase 2 study (NCT01466179) | 19 mo after completion of blinatumomab/ 19 mo after completion of blinatumomab | CD19+/CD34+/CD10(+)/ CD45(+)/cyTdT+/ CD20+ | CD19−/otherwise identical to initial phenotype |
c-ALL, common ALL; cy, cytoplasmic; F, female; GMALL, German multicenter study group for adult ALL; IgM, immunoglobulin M; M, male; TdT, terminal deoxynucleotidyl transferase.